The Impact of Age Over 80 Years on Outcomes in Geriatric Patients with Acute Pancreatitis: A Single Center Experience

Year 2024, Volume: 46 Issue: 2, 284 - 292, 18.03.2024

Hakan Şıvgın Abdurrahman Şahin

https://doi.org/10.20515/otd.1415422

Abstract

The aim of this study is to evaluate the prognosis and mortality of acute pancreatitis (AP) in older subjects and compare octogenarians (≥80 years) with nonoctogenarians (age <80 years). The medical records of elderly patients who were followed up with the diagnosis of AP at our clinic between January 2018 and December 2021 were retrospectively analyzed. The etiology of AP, comorbidities, laboratory parameters, intensive care unit (ICU) admission, and mortality were noted. Among survivors, one-year mortality status was also recorded. Disease severity, in-hospital mortality and one-year mortality were compared. A total of 206 older patients (60 octogenarian, 146 nonoctogenariean) were recruited to the study. Of them, 115 (56%) were female and the mean age was 76.1±7.3 years. Severity of AP didn’t differ between octogenarians and nonctogenarians (p>0.05). ICU admission was seen in 13% of octogenarians and 11% of nonoctogenarians (p>0.05). In-hospital mortality occurred in 8.3% of octogenarians and 6.8% of nonoctogenarians (p>0.05). After discharge, one-year mortality occurred in 20% of octogenarians and 6.6% of nonoctogenarians (p<0.01). In multivariate analysis severe AP (OR:24.940;%95CI:1.013–95.609; p=0.01), ICU admission (OR:10.244;%95CI:1.399–74.990; p=0.01) and chronic kidney disease(CKD) (OR:9.840;%95CI:1.013–95.609; p=0.04) were independent risk factors for in-hospital mortality, and ≥80 years (OR:2.984;%95 CI:1.116–7.980; p =0.03) and neurological disorders (OR:4.424;%95CI:1.480–13.226; p <0.01) were independent factors related to one-year mortality. Our results showed that advenced age has not a significant effect on the course of AP in elderly. Comorbidities play important role in short- and long-term outcomes in elderly. Larger prospective trials are needed to draw more definitive conclusions.

Keywords

Acute pancreatitis, Elderly, Mortality, Octagenarians, Severity

Akut Pankreatitli Geriatrik Hastalarda 80 Yaş Üstü Olmanın Sonuçlar Üzerindeki Etkisi: Tek Merkez Deneyimi

Abstract

Bu çalışmanın amacı yaşlı bireylerde akut pankreatitin (AP) prognozunu ve mortalitesini değerlendirmek ve 80 yaş ve üzeri hastaları, 80 yaş altı hastalarla karşılaştırmaktır. Ocak 2018-Aralık 2021 tarihleri arasında kliniğimizde AP tanısı ile takip edilen yaşlı hastaların tıbbi kayıtları retrospektif olarak incelendi. Akut pankreatit nedeni, komorbiditeler, laboratuvar parametreleri, yoğun bakım ünitesine (YBÜ) yatış ve mortalite kaydedildi. Taburcu edilenlerde bir yıllık sağkalım durumu da kaydedildi. Akut pankreatit şiddeti, hastane mortalitesi ve bir yıllık mortalite karşılaştırıldı. Çalışmaya toplam 206 yaşlı hasta (60’ı 80 yaş üzeri, 146’sı 80 yaş altı) dahil edildi. Bunların 115'i (%56) kadındı ve yaş ortalaması 76.1±7.3 yıldı. AP şiddeti 80 yaş üzeri ve altı hastalar arasında farklılık göstermedi (p>0.05). YBÜ’nde yatış 80 yaş üzeri hastaların %13’ünde, 80 yaş altı hastaların %11’inde mevcuttu (p>0.05). Seksen yaş üzeri hastaların %8.3’ ünde, 80 yaş altı hastaların %6.8’inde hastane mortalitesi meydana geldi (p>0.05). Yaşayan hastalarda, taburculuk sonrası bir yıllık mortalite 80 yaş üzeri olanların %20’sinde ve 80 yaş altı olanların %6.6’ sında görüldü (p<0.01). Çok değişkenli analizde şiddetli AP (OR:24.940; %95CI:1.013–95.609; p=0.01), YBÜ yatışı (OR:10.244; %95CI:1.399–74.990; p=0.01) ve kronik böbrek hastalığı (KBH) (OR:9.840; %95CI:1.013–95.609; p=0.04) hastane mortalitesi için bağımsız risk faktörleriyken, 80 yaş üzeri olmak (OR: 2.984;%95 CI:1.116–7.980; p =0.03) ve nörolojik hastalıklar (OR:4.424;%95CI:1.480–13.226; p <0.01) bir yıllık mortaliteyle ilişkili bağımsız faktörlerdi. Sonuçlarımız ileri yaşın yaşlılarda AP seyri üzerinde belirgin bir etkisinin olmadığını gösterdi. Yaşlılarda, komorbiditeler kısa ve uzun dönem sonuçlarda önemli rol oynamaktadır. Daha kesin sonuçlara varmak için daha büyük prospektif çalışmalara ihtiyaç vardır.

Keywords

Akut pankreatit, Yaşlılar, Mortalite, Seksen Yaş Üzeri, Hastalık Şiddeti

References

• 1. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view. Nature Reviews Rheumatology 2018; 14:107–119.
• 2. Demirelli S, Degirmenci H, Inci S, Arisoy A. Cardiac manifestations in Behcet's disease. Intractable & Rare Diseases Research 2015; 4:70–75. 3. Geri G, Wechsler B, Thi Huong D L, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine 2012; 91:25–34.
• 4. Kechida M, Salah S, Kahloun R, Klii R, Hammami S, Khochtali I. Cardiac and vascular complications of Behçet disease in the Tunisian context: clinical characteristics and predictive factors. Advances in Rheumatology (London, England) 2018; 58: 32.
• 5. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Annals of the Rheumatic Diseases 2018; 77:808–818.
• 6. International Study Group for Behçet's Disease Criteria for diagnosis of Behçet's disease. Lancet (London, England) 1990; 335:1078–1080.
• 7. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology: JEADV 2014; 28: 338–347.
• 8. Lakhanpal S, Tani K, Lie J. T, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Human Pathology 1985;16: 790–795.
• 9. Mogulkoc N, Burgess M. I, Bishop P. W. Intracardiac thrombus in Behçet's disease: a systematic review. Chest 2000; 118: 479–487.
• 10. Yıldırım R, Oğuzman S, Dinler M, Bilge NŞY, Kaşifoğlu T. Scoping beyond pulmonary artery involvement; pulmonary involvement in Behcet's disease; a retrospective analysis of 28 patients. Clin Rheumatol 2023; 42:849-853
• 11. Bletry O, Mohattane A, Wechsler B, et al. Atteinte cardiaque de la maladie de Behçet. Douze observations [Cardiac involvement in Behçet's disease. 12 cases]. Presse Medicale (Paris, France: 1983), 1988;17: 2388–2391.
• 12. Gürgün C, Ercan E, Ceyhan C, et al. Cardiovascular involvement in Behçet's disease. Japanese Heart Journal 2002; 43: 389–398.
• 13. Emmungil H, Yaşar Bilge NŞ, Küçükşahin O, et al. A rare but serious manifestation of Behçet's disease: intracardiac thrombus in 22 patients. Clinical and Experimental Rheumatology 2014;32: S87–S92.
• 14. Aksu T, Tufekcioglu O. Intracardiac thrombus in Behçet's disease: four new cases and a comprehensive literature review. Rheumatology International 2015; 35: 1269–1279.
• 15. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine 2012; 91:35–48.
• 16. Erbilen E, Albayrak S, Gulcan E, et al. Acute coronary stenosis in a young man with Behçet's syndrome. Medical principles and practice: international journal of the Kuwait University, Health Science Centre 2008; 17: 157–160.
• 17. Calgüneri M, Aydemir K, Oztürk M A, Haznedaroğlu IC, Kiraz S, Ertenli I. Myocardial infarction and deep venous thrombosis in a young patient with Behçet disease. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006; 12: 105–109.
• 18. Güllü I H, Benekli M, Müderrisoğlu H, et al. Silent myocardial ischemia in Behçet's disease. The Journal of Rheumatology 1996; 23: 323–327.
• 19. Chen H, Zhang Y, Li C, et al. Coronary involvement in patients with Behçet's disease. Clinical Rheumatology 2019; 38: 2835–2841.
• 20. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clinical Rheumatology 2008; 27: 201–205.
• 21. Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis and Rheumatism 2012; 64: 2753–2760.
• 22. Assar S, Sadeghi B, Davatchi F, et al. The association of pathergy reaction and active clinical presentations of Behçet's disease. Reumatologia. 2017; 55: 79-83.
• 23. Gheita TA, El-Latif EA, El-Gazzar II, et al. Egyptian College of Rheumatology-Behçet’s Disease Study Group (ECR-BDSG). Behçet's disease in Egypt: a multicenter nationwide study on 1526 adult patients and review of the literature. Clin Rheumatol. 2019; 38: 2565-2575.